GAL-101 is under clinical development by Galimedix Therapeutics and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect GAL-101’s likelihood of approval (LoA) and phase transition for Glaucoma took place on 03 Feb 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their GAL-101 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

GAL-101 overview

GAL-101 is under development for the treatment of glaucoma and dry age-related macular degeneration. The drug candidate is formulated as eye drops and is administered through ophthalmic route. It acts by targeting amyloid beta peptide (amyloid precursor protein).

The drug candidate was also under development for Alzheimers disease and Alzheimer-induced dementia.

Quick View GAL-101 LOA Data

Report Segments
  • Innovator
Drug Name
  • GAL-101
Administration Pathway
  • Ophthalmic
Therapeutic Areas
  • Central Nervous System
  • Ophthalmology
Key Developers
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.